EU regulators scrap merger power aimed at killer acquisitions after court veto

Earnings call: Illumina reports mixed Q3 results, plans for future growth

Illumina's Q3 2024 earnings reveal a slight revenue decline, but positive adjustments in operating margin and EPS guidance indicate strategic growth amidst competitive pressures.

Illumina shares fall 5% as Q4 revenue guidance disappoints

Illumina's Q3 earnings surpassed estimates, but shares fell due to weak Q4 revenue guidance. Adjusted EPS rose, while full-year revenue outlook was lowered amid macroeconomic constraints.

Illumina earnings beat by $0.26, revenue was in line with estimates

Illumina's Q3 EPS was $1.14, beating estimates. Revenue matched at $1.08B. Q4 revenue guidance is $1.07B. Stock rose 35.08% over the past year.

NXP, Illumina, Vertex set to report earnings Monday

Key companies are reporting earnings soon, including NXP Semiconductors and Marriott. Stay updated with real-time market information and consider using InvestingPro for insights.

Corvex founder Meister sees big upside for stocks already targeted by others

Michael C. Burgess makes a stock sale in Illumina, Inc.

Michael C. Burgess sold stock in Illumina, Inc., reflecting significant market activity and investor interest in the genomics sector amid mixed financial signals.

Top EU court sides with U.S. biotech group Illumina in Grail legal battle

Illumina's shares rose after the EU court ruled against the Commission's attempt to block its $7.1 billion acquisition of Grail, marking a legal victory for the company.

Illumina wins Grail battle in blow to EU merger power

Illumina successfully challenged the EU's scrutiny of its $7.1 billion Grail acquisition, limiting EU merger powers and nullifying a related fine.